Vischer on Memo Therapeutics’ extension funding round
Vischer advised the main investors on the extension of Memo Therapeutics’ series C financing round, raising CHF20 million and bringing the total amount raised in the funding round to CHF 45m.
Vischer’s team
Vischer’s team comprised corporate / M&A partner Dr. Matthias Staehelin (pictured), corporate / M&A managing associate Vincent S. Reardon, corporate / M&A associate Lucas M. Sturzenegger and tax counsel Adrian Briner.
About Memo Therapeutics
Founded in 2012, Memo Therapeutics is a late-stage biotech company developing best-in-class BKV-neutralizing anti-body for BKV infection in kidney transplantation. The proceeds will be used to expand the Phase II clinical development of Memo Therapeutics AG’s best-in-class anti-BK Virus antibody.
